MedTrace Logo

The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment

NCT07788573 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2026-08-26

No results posted yet for this study

Summary

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) and the leading non-traumatic cause of neurological disability in young adults. Historically considered a T-cell-mediated disease, the paradigm for MS has shifted thanks to the efficacy of therapies targeting B cells. The investigators recently identified FCRL5 as a B-cell-specific biomarker that is significantly elevated in the cerebrospinal fluid (CSF) of patients with relapsing-remitting MS and is independently associated with an increased risk of developing new MRI lesions within two years of diagnosis (ref. Deltombe et al., PMID: 41004694). This project aims to further explore FCRL5 as a prognostic biomarker, study the role of FCRL5-expressing B cells in MS pathogenesis and the effects of disease-modifying therapies on these subsets.

Conditions

Interventions

OTHER

A blood test every 6 months for MS patients.

A blood test every 6 months for MS patients : Day1, Month 6, Month 12 and Month 24

OTHER

A single blood draw for the healthy volunteer

A single blood draw for the healthy volunteer

OTHER

A single blood draw for the group of volunteers with Sjögren's syndrome

A single blood draw for the group of volunteers with Sjögren's syndrome

Sponsors & Collaborators

  • Université Catholique de Louvain

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07788573 on ClinicalTrials.gov